VistaGen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · IEX Real-Time Price · USD
3.660
-0.040 (-1.08%)
At close: Jul 19, 2024, 4:00 PM
3.540
-0.120 (-3.28%)
Pre-market: Jul 20, 2024, 9:29 AM EDT

VistaGen Therapeutics Income Statement

Millions USD. Fiscal year is Apr - Mar.
Year Ending
TTM Mar 31, 2024Mar 31, 2023Mar 31, 2022Mar 31, 2021Mar 31, 2020 2018 - 2010
Revenue
1.061.06-0.231.111.090
Upgrade
Revenue Growth (YoY)
---1.78%--
Upgrade
Gross Profit
1.061.06-0.231.111.090
Upgrade
Selling, General & Admin
14.0614.0614.6613.487.17.43
Upgrade
Research & Development
20.0220.0244.3835.4111.9313.37
Upgrade
Operating Expenses
34.0934.0959.0448.8919.0220.8
Upgrade
Operating Income
-33.02-33.02-59.27-47.78-17.93-20.8
Upgrade
Other Expense / Income
-3.66-3.66-0.03-0.02-0-0.03
Upgrade
Pretax Income
-29.36-29.36-59.24-47.76-17.93-20.77
Upgrade
Income Tax
000.01000
Upgrade
Net Income
-29.36-29.36-59.25-47.76-17.93-20.77
Upgrade
Preferred Dividends
0000.9524.391.26
Upgrade
Net Income Common
-29.36-29.36-59.25-48.71-42.32-22.04
Upgrade
Shares Outstanding (Basic)
19197732
Upgrade
Shares Outstanding (Diluted)
1919773-
Upgrade
Shares Change
178.13%178.13%5.45%129.85%79.58%67.92%
Upgrade
EPS (Basic)
-1.52-1.52-8.51-7.38-14.70-15.00
Upgrade
EPS (Diluted)
-1.52-1.52-8.51-7.38-14.70-15.00
Upgrade
Free Cash Flow
-25.87-25.87-49.93-45.46-12.35-15.76
Upgrade
Free Cash Flow Per Share
-1.34-1.34-7.17-6.89-4.30-9.86
Upgrade
Gross Margin
100.00%100.00%-100.00%100.00%-
Upgrade
Operating Margin
-3103.48%-3103.48%--4308.68%-1646.06%-
Upgrade
Profit Margin
-2759.59%-2759.59%--4392.42%-3884.33%-
Upgrade
Free Cash Flow Margin
-2431.77%-2431.77%--4099.28%-1133.45%-
Upgrade
EBITDA
-28.79-28.79-58.71-47.05-17.45-20.67
Upgrade
EBITDA Margin
-2705.83%-2705.83%--4242.75%-1602.02%-
Upgrade
Depreciation & Amortization
0.570.570.530.710.480.1
Upgrade
EBIT
-29.36-29.36-59.24-47.76-17.93-20.77
Upgrade
EBIT Margin
-2759.21%-2759.21%--4306.88%-1645.86%-
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).